Production (Stage)
Cytek Biosciences, Inc.
CTKB
$2.42
-$0.03-1.22%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -7.59% | -1.30% | 7.29% | -6.19% | 20.96% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -7.59% | -1.30% | 7.29% | -6.19% | 20.96% |
| Cost of Revenue | -2.50% | -5.40% | 8.03% | -1.63% | 36.12% |
| Gross Profit | -12.41% | 1.83% | 6.72% | -9.68% | 9.39% |
| SG&A Expenses | 6.08% | 5.50% | 4.21% | -4.74% | 3.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.51% | -2.19% | 2.44% | -6.25% | 12.88% |
| Operating Income | -39.51% | 381.75% | 33.83% | 6.57% | 11.74% |
| Income Before Tax | -25.28% | 151.11% | 103.75% | -8.96% | 0.52% |
| Income Tax Expenses | 104.82% | 148.85% | -134.52% | 247.17% | -26.47% |
| Earnings from Continuing Operations | -84.83% | 75.23% | 114.58% | -137.78% | 9.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -84.83% | 75.23% | 114.58% | -137.78% | 9.37% |
| EBIT | -39.51% | 381.75% | 33.83% | 6.57% | 11.74% |
| EBITDA | -44.99% | 49.93% | 48.48% | 10.15% | 19.05% |
| EPS Basic | -88.54% | 81.31% | 115.19% | -145.82% | 6.18% |
| Normalized Basic EPS | -27.97% | 94.79% | 103.65% | -12.87% | -2.88% |
| EPS Diluted | -80.00% | 73.48% | 114.40% | -147.68% | 0.40% |
| Normalized Diluted EPS | -27.97% | 94.79% | 103.65% | -12.87% | -2.88% |
| Average Basic Shares Outstanding | -1.97% | -3.34% | -3.80% | -3.29% | -3.37% |
| Average Diluted Shares Outstanding | -1.97% | -3.34% | -2.49% | -3.29% | -3.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |